ID.1
Item
diagnosis of type 2 diabetes mellitus at the discretion of the investigator for at least 26 weeks prior to screening (visit 1)
boolean
ID.2
Item
treatment with basal insulin for at least 12 weeks prior to randomisation with or without metformin, sulphonylurea (su)/glinide, dpp-4 inhibitors, alfa-glucosidase-inhibitors
boolean
ID.3
Item
hba1c 7.0% - 10.0%
boolean
ID.4
Item
body mass index (bmi) less than or equal to 40.0 kg/m^2
boolean
ID.5
Item
treatment with glucose-lowering agent(s) other than those stated in the inclusion criteria
boolean
ID.6
Item
stroke; heart failure new york heart association (nyha) class iii or iv; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty
boolean
ID.7
Item
chronic disorder or disease which might jeopardise safety or compliance
boolean
ID.8
Item
malignant neoplasms
boolean
ID.9
Item
recurrent severe hypoglycaemia
boolean